CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BCAL Diagnostics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BCAL Diagnostics Ltd
Suite 506, Level 5, 50 Clarence Street
SYDNEY, NSW  2000  Australia Ticker: BDXBDX
Business Summary
BCAL Diagnostics Limited is an Australia-based biotechnology company. The Company develops early, non-invasive blood test-based diagnostic technologies designed to complement mammograms and improve breast cancer screening outcomes. Its commercial laboratory, equipped with Liquid Chromatography Mass Spectrometry (LCMS) technology, is focused on scientific innovation and clinical service delivery, supporting both ongoing research and the commercial rollout of our diagnostic test. The Company develops a blood test for breast cancer screening and diagnosis. The assay measures a panel of lipids in blood plasma using Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). Its lipid measurements are converted to a test score using a proprietary diagnostic algorithm. It offers BREASTEST plus, which is a blood test designed to be used alongside a mammogram in breast cancer screening. It provides information for women with dense breasts to help rule out the presence of breast cancer.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20256/30/2025Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
3826 Laboratory analytical instruments
8049 Offices and clinics of health practitioners, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board JayneShaw 7/1/2026 2/15/2010
Director Clinical Affairs Breast Cancer ShaneRyan 6/1/2026 9/21/2023
Chief Financial Officer, Company Secretary Guy A.Robertson 3/16/2021 3/16/2021
5 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 368,067,640 (As of 12/31/2025)
Shareholders: 1,139
Stock Exchange: ASX


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026